Antirheumatic Drugs, Disease-Modifying

Known as: Drugs, Disease-Modifying Antirheumatic, Disease-Modifying, Antirheumatic Second-Line Drugs, dmards 
A pharmaceutical agent that is categorized by its ability to alter the progression of autoimmune disease.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
OBJECTIVES To assess the safety of synthetic (s) and biological (b) disease-modifying antirheumatic drugs (DMARDs) for the… (More)
  • table 2
Is this relevant?
Highly Cited
2011
Highly Cited
2011
CONTEXT Rheumatoid arthritis (RA) and psoriasis have been linked with insulin resistance and diabetes mellitus (DM). Prior… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2008
Highly Cited
2008
OBJECTIVE To examine the efficacy and safety of the humanized anti-interleukin-6 receptor antibody tocilizumab combined with… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
OBJECTIVE More timely and effective therapy for rheumatoid arthritis (RA) has contributed to increasing rates of clinical… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2005
Highly Cited
2004
Highly Cited
2004
OBJECTIVE Delay of disease-modifying anti-rheumatic drug (DMARD) therapy is a major contributing factor for poor outcome in… (More)
  • table 1
  • figure 2
  • figure 1
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
OBJECTIVE To evaluate the efficacy and safety of monotherapy with adalimumab in patients with RA for whom previous DMARD… (More)
  • table 1
  • figure 1
  • table 2
  • figure 3
  • figure 2
Is this relevant?
Highly Cited
2002
Highly Cited
2002
OBJECTIVE To study the impacts of 1) the delay from the onset of symptoms to the institution of disease-modifying antirheumatic… (More)
Is this relevant?